Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …

Erlotinib and gefitinib are among the most widely researched, used and available
molecularly targeted therapies for treatment of advanced non-small cell lung cancer …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Purpose: This multicenter, phase II study evaluates the efficacy and safety of erlotinib, an
epidermal growth factor receptor (EGFR) inhibitor, plus sorafenib, a multityrosine kinase …

Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

Molecular targeted therapies, such as the epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs), provide a different mechanism of action from chemotherapy and can …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Introduction The introduction of epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs) has improved the outlook for patients with advanced non-small-cell lung …

Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI),
gefitinib and erlotinib have been tested as maintenance therapy in patients with advanced …